SCHEMBL25510486

SCHEMBL25510486

Cc1ccc(C(C)C)c(N2CCCCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 3/20 0.41
KDM4E B2RXH2 2/20 0.41
RECQL P46063 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPY5R Q15761 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
OPRK1 P41145 1/20 0.39
TSHR P16473 3/20 0.39
MAPK1 P28482 2/20 0.39
CASP1 P29466 2/20 0.39
HTT P42858 1/20 0.39
MAPT P10636 1/20 0.39
CASP7 P55210 1/20 0.39
GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20365554 0.83 ALDH1A1 (0.46) ALDH1A1HPGDHSD17B10KDM4EL3MBTL1
SCHEMBL21725515 0.76 TRPV1 (0.42) ALDH1A1HPGDHSD17B10KDM4EL3MBTL1
SCHEMBL19665161 0.75 CYP1A2 (0.42) SMN1; SMN2CYP1A2ALDH1A1HPGDHSD17B10
SCHEMBL15831861 0.75 CNR2 (0.52) SMN1; SMN2CYP1A2ALDH1A1HPGDHSD17B10
SCHEMBL3948488 0.73 CYP1A2 (0.44) SMN1; SMN2CYP1A2ALDH1A1HPGDHSD17B10
SCHEMBL2609324 0.72 CYP1A2 (0.51) SMN1; SMN2CYP1A2ALDH1A1HPGDHSD17B10
SCHEMBL14883192 0.71 HCRTR1 (0.36) HPGDHSD17B10KDM4E
SCHEMBL7066926 0.71 HRH4 (0.60) SMN1; SMN2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL14781363 0.71 HRH4 (0.60) SMN1; SMN2ALDH1A1HPGDHSD17B10KDM4E
SCHEMBL2553146 0.71 HRH4 (0.60) SMN1; SMN2ALDH1A1HPGDHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT JMACKEM CO., LTD (KR) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147428-A1 BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT TRPV1, TRPA1, TRPV5 SMN1; SMN2 3669/4885CYP1A2 1443/4885ALDH1A1 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.